Pharmacologic study (JP28927) of alectinib in Japanese patients with ALK+ non‐small‐cell lung cancer with or without prior crizotinib therapy

We report pharmacokinetics, efficacy and safety data for a new 150‐mg alectinib capsule in ALK+ non‐small‐cell lung cancer in a multicenter, open‐label pharmacologic study (JP28927). Eligible patients (≥20 years, locally advanced/metastatic ALK+ disease, ALK inhibitor‐naïve and ‐pretreated [includin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Sci
Asıl Yazarlar: Hida, Toyoaki, Nakagawa, Kazuhiko, Seto, Takashi, Satouchi, Miyako, Nishio, Makoto, Hotta, Katsuyuki, Takahashi, Toshiaki, Ohe, Yuichiro, Takeda, Koji, Tatsuno, Masahiro, Asakawa, Takashi, Shimada, Tadashi, Tanaka, Tomohiro, Tamura, Tomohide
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2016
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5132270/
https://ncbi.nlm.nih.gov/pubmed/27566263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13066
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller